Aortic Stenosis Treatment and guidelines

Interventional options and guidelines are continually evolving in aortic stenosis (AS). Access the key updates on aortic stenosis management in the 2021 ESC/EACTS guidelines, including the evidence that supported this change and the importance of a shared decision-making process with your patients.

2021 ESC/EACTS guidelines in practice

TF-TAVI is now a Class IA recommendation, for patients with severe aortic stenosis (sAS) ≥75 years of age^**, as well as for additional patient groups < 75 years of age.¹ Read more about the changes and how they could impact your everyday clinical practice.
^**Based on evaluation of clinical, anatomical and procedural factors

Diagnosing aortic stenosis patients

The ESC/EACTS guidelines continue to recommend echocardiography as a key tool in confirming AS diagnosis and severity, guiding treatment choices and indicating when intervention is needed.¹

Interventional options for aortic valve replacement (AVR)

The updated 2021 ESC/EACTS Guidelines for the treatment of sAS highlight the role of the Heart Team and patient choice on treatment decisions.¹

Find out more about the current treatment options for your patients with sAS, and considerations of the Heart Team when deciding between TAVI and surgery (SAVR).

Transfemoral TAVI (TF-TAVI) procedure using balloon-expandable technology with SAPIEN 3 Platform

Watch now

Interventional options for aortic valve replacement (AVR)

The updated 2021 ESC/EACTS Guidelines for the treatment of sAS highlight the role of the Heart Team and patient choice on treatment decisions.¹

Find out more about the current treatment options for your patients with sAS, and considerations of the Heart Team when deciding between TAVI and surgery (SAVR).

Transfemoral TAVI (TF-TAVI) procedure using balloon-expandable technology with SAPIEN 3 Platform

Watch now

Stay informed with our newsletter

For signing up to the monthly Edwards Lifesciences TAVI newsletter. You will now receive emails on the latest developments and industry insights on aortic stenosis

Terms and conditions

By providing your personal information, you agree to allow Edwards Lifesciences and its agents to use this information to communicate with you in the future, including information about services, events, and programs. Edwards Lifesciences and its agents will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Edwards Lifesciences and its agents, Edwards Lifesciences will use your information in accordance with the Edwards privacy policy.

Our monthly updates provide you the latest developments in TAVI and aortic stenosis. Read more

References

1Vahanian A, et al. Eur Heart J. 2021; ehab395. doi:10.1093/eurheartj/ehab395.

Aortic Stenosis Treatment and guidelines

2021 ESC/EACTS guidelines in practice

Diagnosing aortic stenosis patients

Interventional options for aortic valve replacement (AVR)

Interventional options for aortic valve replacement (AVR)

Stay informed with our newsletter

Thank you!

References

Help us create better content with 3 short questions.